Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMorgan Advanced Materials Regulatory News (MGAM)

Share Price Information for Morgan Advanced Materials (MGAM)

Share Price is delayed by 15 minutes
Get Live Data
229.00    1.00 (0.44%)
Bid:
228.50
Ask:
229.50
Spread: 1.00 (0.438%)
Market Cap: £632.99m
MGAM Live PriceLast checked at - London Stock Exchange

Intraday Morgan Advanced Materials Share Chart

Strategy Update

4 Dec 2025 07:00

RNS Number : 1624K
Morgan Advanced Materials PLC
04 December 2025
 

Press Release

Morgan Advanced Materials plc

4 December 2025

Strategy Update

Unlocking our potential

Morgan Advanced Materials plc, the global leader in advanced ceramics and carbon systems for technologically demanding applications, is today holding a Strategy Update in London. Participation in the event is by invitation only for institutional analysts and investors.

Damien Caby, Chief Executive Officer and Richard Armitage, Chief Financial Officer will host the event. They will present Morgan's strategy for sustainable growth, focussing on:

Transforming our operational effectiveness to turnaround underperforming sites and improve our supply chain effectiveness

Driving stronger growth by focusing on our right to win to enhance our value proposition, strengthening partnerships, and expanding in the right areas to gain share

Maximising our portfolio through partnerships, divestments and bolt-on M&A

They will also set out an updated financial framework and re‐iterate our capital allocation priorities:

Above Market Organic Revenue Growth. We expect to achieve growth in excess of GDP

Attractive Margins. We expect to achieve adjusted operating profit margin of 12% by 2028 with sustainable adjusted operating profit margins of between 12% and 14% beyond 2028

Delivering EPS Growth. Achieving sustained growth in adjusted Earnings per Share, ahead of organic revenue growth, driven by a combination of organic growth, margin accretion, shareholder returns and M&A

Sustaining ROIC. 17% ‐ 20% ROIC

Leverage Range. 1.0x to 1.5x, or up to 2.0x adjusted EBITDA post-acquisition, utilising our strong balance sheet to fund our organic growth, and then over time deploying excess capital to fund incremental M&A or additional shareholder returns as appropriate

Dividend Cover. Shareholder dividends maintained then growing with adjusted earnings at around 2.5x cover

We intend to pause our buy-back programme as part of our focus on balance sheet resilience. The programme will be paused after the completion of the second tranche, by which time we will have purchased £20m of shares.

No new information on current year trading will be shared at the event.

Damien Caby, Chief Executive Officer, commented:

"Morgan is an exciting innovative company with distinctive capabilities and competitive advantages that give us a decisive right to win across our diverse markets. However, we have not been delivering to our ambition or to our full potential. Much of this value can be achieved through more rigorous customer focus and portfolio management. I will set out today a clear strategy focussing on unlocking the Group's potential by focussing on transformation of operational effectiveness, driving stronger growth and the maximisation of portfolio value. This will help us improve the financial performance of the group on a more sustainable basis to deliver against a revised financial framework."

The presentation will be made available at www.morganadvancedmaterials.com at 2pm today, along with a recording of the presentation that will be made available following the event.

 

For further enquiries:

Richard Armitage, CFO

Morgan Advanced Materials

01753 837 000

Nicholas Frost, Investor Relations

 

 

 

 

Nina Coad

Brunswick

0207 404 5959

 

Important notice:

This announcement contains forward-looking statements. These statements have been made in good faith based on the information available up to the time of the approval of this announcement. No assurance can be given that these expectations will prove to have been correct. By their nature, forward-looking statements involve risks, uncertainties or assumptions that could cause actual results to differ materially from those expressed or implied by these forward-looking statements. As such, undue reliance should not be placed on forward-looking statements.

The Directors undertake no obligation to update any forward-looking statements whether as a result of new information, future events or otherwise.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDKXLFBELLZFBD
Date   Source Headline
28th Apr 20209:15 amRNSDisclosure of Rights Attached to Listed Securities
9th Apr 20201:33 pmRNSNotice of AGM
2nd Apr 20205:01 pmRNSDirector/PDMR Shareholding
1st Apr 20201:04 pmRNSAnnual Financial Report
31st Mar 20207:00 amRNSCOVID-19 Update
20th Mar 20204:47 pmRNSSecond Price Monitoring Extn
20th Mar 20204:39 pmRNSPrice Monitoring Extension
19th Mar 202012:22 pmRNSDirector/PDMR Shareholding
12th Mar 202010:14 amRNSDirector/PDMR Shareholding
11th Mar 202010:57 amRNSDirector/PDMR Shareholding
3rd Mar 20205:29 pmRNSDirector/PDMR Shareholding
25th Feb 20207:00 amRNSFull-year Results
16th Dec 20199:10 amRNSBlock listing Interim Review
2nd Dec 20199:10 amRNSDirector Declaration
18th Nov 201911:00 amRNSDirector/PDMR Shareholding
13th Nov 20199:48 amRNSDirector/PDMR Shareholding
12th Nov 201912:23 pmRNSDirector/PDMR Shareholding
11th Nov 20194:04 pmRNSDirector/PDMR Shareholding
11th Nov 20192:44 pmRNSDirector/PDMR Shareholding
8th Nov 20197:00 amRNSTrading Update
23rd Oct 20191:56 pmRNSHolding(s) in Company
23rd Oct 20191:54 pmRNSHolding(s) in Company
23rd Sep 201912:03 pmRNSDirector/PDMR Shareholding
3rd Sep 20192:21 pmRNSHolding(s) in Company
25th Jul 20197:00 amRNSHalf-year Report
17th Jun 20198:06 amRNSBlock listing Interim Review
7th Jun 20199:38 amRNSHolding(s) in Company
24th May 20191:08 pmRNSDirector/PDMR Shareholding
10th May 201912:14 pmRNSResult of AGM
10th May 20197:00 amRNSTrading Update
7th May 20194:36 pmRNSDirectorate Change
8th Apr 20195:29 pmRNSDirector/PDMR Shareholding
3rd Apr 201911:22 amRNSAnnual Financial Report
19th Mar 20199:47 amRNSDirector/PDMR Shareholding
19th Mar 20199:44 amRNSDirector/PDMR Shareholding
26th Feb 20197:00 amRNSFinal Results
17th Dec 201810:51 amRNSBlock listing Interim Review
21st Nov 20182:36 pmRNSDirector/PDMR Shareholding
21st Nov 20187:00 amRNSDivestment of Composites and Defence Systems
9th Nov 20187:00 amRNSTrading Update
22nd Oct 20185:17 pmRNSHolding(s) in Company
28th Sep 20188:17 amRNSCompletion of Bank Refinancing
6th Aug 20189:24 amRNSDirector/PDMR Shareholding
1st Aug 20188:54 amRNSDirector/PDMR Shareholding
26th Jul 20187:00 amRNSHalf-year results
2nd Jul 20182:37 pmRNS2017 Environmental, Health and Safety Report
2nd Jul 20187:00 amRNSDirectorate Change
15th Jun 20189:00 amRNSBlock listing Interim Review
11th May 20181:32 pmRNSResult of AGM
1st May 20182:08 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.